>
Switch to:

Johnson & Johnson GF Value

: $163.14 (As of Today)
View and export this data going back to 1944. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2021-10-23), Johnson & Johnson's share price is $163.72. Johnson & Johnson's GF Value is $163.14. Therefore, Johnson & Johnson's Price-to-GF-Value for today is 1.00.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Johnson & Johnson is Fairly Valued.

Johnson & Johnson  (NYSE:JNJ) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Johnson & Johnson's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=163.72/163.14
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson GF Value Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson Business Description

Johnson & Johnson logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Comparable Companies
NYSE:PFE NYSE:MRK NYSE:ABBV NYSE:LLY NYSE:BMY NAS:AMGN NAS:GILD NYSE:AGN NAS:BIIB NAS:HZNP XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 FRA:A60 XTER:BAYN SHSE:600276 TSE:4568
Traded in Other Exchanges
JNJ:Peru JNJ:Mexico 0R34:UK JNJ:Germany JNJ:Chile JNJB34:Brazil JNJ:Austria JNJ:Argentina
Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Website
http://www.jnj.com
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.
Executives
Weinberger Mark A director METLIFE, INC. 200 PARK AVENUE NEW YORK NY 10166
Hewson Marillyn A director C/O CARPENTER TECHNOLOGY CORPORATION PO BOX 14662 READING PA 19612-4662
Washington A. Eugene director ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wengel Kathryn E officer: EVP, Chief GSC Officer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mcevoy Ashley officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Perez William D director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: PEREZ WILLIAM D a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mongon Thibaut officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Stoffels Paulus officer: Vice Chair, Exec Committee ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Ullmann Michael H officer: Exec VP, General Counsel JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Fasolo Peter officer: Exec VP, Chief HR Officer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wolk Joseph J officer: Exec VP, CFO JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Taubert Jennifer L officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Sneed Michael E officer: EVP, Global Corp Aff & COO JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Decker Robert J officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Gorsky Alex director, officer: Chairman, CEO JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933

Johnson & Johnson Headlines

From GuruFocus

Johnson & Johnson Faces Class-Action Lawsuit Over Benzene-Tainted Neutrogena and Aveeno Sunscreen Products

By PRNewswire 07-15-2021

Women Cancer Victims Opposed to Johnson & Johnson's 'Texas Two-Step' Bankruptcy Ploy Urge Passage of Reforms Introduced by Warren, Durbin, Nadler, Blumenthal, and Maloney

By PRNewswire 07-29-2021

America First Investment Advisors, LLC Buys Johnson & Johnson, iShares Core U.S. Aggregate Bond ETF, Oracle Corp, Sells iShares 1-3 Year Treasury Bond ETF, Expeditors International of Washington Inc, Union Pacific Corp

By insider 04-28-2021

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

By PRNewswire 07-02-2021

PineBridge Investments, L.P. Buys Johnson & Johnson, iShares MSCI Mexico ETF, iShares 1-3 Year Treasury Bond ETF, Sells Kingsoft Cloud Holdings, AGNC Investment Corp, UnitedHealth Group Inc

By insider 05-17-2021

Lawyers for Ovarian Cancer Victims Call on Regulators to Stop 'Contemptible' Johnson & Johnson Bankruptcy Plan

By PRNewswire 07-19-2021

Legacy Financial Advisors, Inc. Buys BTC iShares U.S. Treasury Bond ETF, Vanguard Dividend Appreciation FTF, Johnson & Johnson, Sells BTC iShares MSCI Emerging Markets Min Vol Factor E, iShares Core MSCI Emerging Markets ETF, Truist Financial Corp

By insider 04-28-2021

Portnoy Law: Lawsuit Filed On Behalf of Johnson & Johnson Consumer, Inc. Investors

By Marketwired 07-22-2021

Yacktman Holding Johnson & Johnson Rises on 2nd-Quarter Earnings Beat

By 07-21-2021

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

By PRNewswire 06-09-2021

Other Sources

Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit

By Zacks 2021-07-30

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

By Zacks 2021-07-27

Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance

By Zacks 2021-08-10

Lilly's (LLY) Jardiance Gets FDA Approval for Heart Failure

By Zacks 2021-08-19

FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues

By Zacks 2021-08-05

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

By Zacks 2021-08-04

3 of the Best Stocks You Can Buy With $200 or Less

By Fool 2021-08-11

US Set to Receive COVID-19 Vaccine Booster Dose Next Month

By Zacks 2021-08-19

Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?

By Zacks 2021-08-20

Moderna (MRNA) Gets EUA for Third Dose of COVID-19 Vaccine

By Zacks 2021-08-16

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

By Zacks 2021-07-27

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

By Zacks 2021-08-04

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

By Zacks 2021-07-28

Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?

By Zacks 2021-08-04

Should Oshares U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?

By Zacks 2021-08-06

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)